论文部分内容阅读
目的 研究人直肠癌相关抗原单克隆抗体 (HM 93- 4McAb)的特异性 ,为生物导向诊断、治疗奠定基础。方法 应用 (HM93- 4McAb)与 85例人直肠癌标本进行间接免疫荧光技术检测。结果 (1)DukesC期 (HM93- 4McAb)体阳性率 96 .2 %明显高于A期、B期 (47.6 % ,6 0 % ) ,与D期 88.8%比较无明显差异性。 (2 )中分化腺癌阳性率 10 0 %明显高于高分化腺癌及粘液癌 (P <0 .0 1)。 (3)直肠癌相关抗原的高表达与患者预后有明显的关系。结论 HM93- 4McAb可用于直肠癌的临床免疫病理分型诊断、药物标记生物导向诊断与治疗的载体。
Objective To study the specificity of human rectal cancer-associated antigen monoclonal antibody (HM 93-4 McAb) and lay a foundation for bio-directed diagnosis and treatment. Methods Indirect immunofluorescence technique was used to detect (HM93-4 McAb) and 85 cases of human rectal cancer. Results (1) The positive rate of HM93-4 McAb was 96.2%, which was significantly higher than that of stage A and B (47.6%, 60%). There was no significant difference compared with 88.8% of stage D. (2) The positive rate of moderately differentiated adenocarcinoma was 100% higher than that of well-differentiated adenocarcinoma and mucinous carcinoma (P < 0.01). (3) The high expression of rectal cancer associated antigen has a significant relationship with the prognosis of patients. Conclusion HM93-4 McAb can be used for the diagnosis of clinical immunopathological typing of rectal cancer, and the carrier for biomarker-guided biomarker diagnosis and treatment.